|Last Price$130.10||Day Change (%)1.21%|
|Open Price$129.61||Day Change ($)1.56|
|Day Range129.24–130.35||52-Week Range100.51–142.75|
As of Thu 04/17/2014 02:59 PM EST | USD
A handful of health-care names are selling at premiums now, but buying opportunities are surfacing, as well.
Genzyme to Resubmit LemtradaTM Application for FDA Review
More than a dozen analyst-approved foreign large-cap funds own these names.
The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.
Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session
Research and Markets: Concise Analysis of the Chinese Antidiabetic Drug Market
Research and Markets: Crop Protection South America Monthly Report
Research and Markets: Magnetic Resonance Imaging (MRI) System Advances Market Forecasts & Opportunities, 2018
The diversified health-care firm remains remarkably profitable in tough industries.
Brand recognition and product innovation keep the firm's moat wide.